中文字幕av一区二区三区人妻少妇_97精品人人妻人人_老熟妇高潮一区二区三区_亚洲处破女av日韩精品

CN / EN

News

Technoderma Medicines Completes Phase 1 Dose Escalation Clinical Trial of TDM-180935 for Atopic Dermatitis

Release time: 2023-12-06 Article source: 特科羅

CHENGDU – December 04, 2023 (XYZ Newswire) Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed a Phase 1 clinical trial (NCT05525468) of TDM-180935 topical ointment for Atopic Dermatitis (AD). This first clinical trial in the AD program included single dose and multidose escalation cohorts in a study entitled, “A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-180935 Following Topical Administration in Healthy Male Subjects”. Study objectives were to evaluate safety and pharmacokinetics of topical TDM-180935; one U.S. clinical site participated in this study under an open IND with FDA. All strengths of TDM-180935 (0.25%-2.0%) were well tolerated with no material safety issues identified. Bioanalytical results show that once daily application of TDM-180935 for 4 weeks over the range of doses studied produces extremely low to no systemic exposure.

Arthur P. Bertolino, MD, PhD, MBA, Chief Medical Officer at Technoderma Medicines commented, “We  are excited to see that TDM-180935 has met our expectations of a favorable safety profile in the current Phase 1 testing. As a potent JAK1/Tyk2 small molecule inhibitor, it may offer significant advantages regarding efficacy and safety compared to existing topical treatments for Atopic Dermatitis.”

“This is a major milestone for the Company as we can now transition our second clinical program into Phase 2. We continue to build a robust and sustainable pipeline of drug candidates in multiple phases of clinical development,” said Zengquan Wang, PhD, Chief Executive Officer at Technoderma Medicines. “We are well on our way to produce a portfolio of dermatology drug candidates.”

About TDM-180935

TDM 180935 is a small molecule drug candidate being developed as a topical drug for treatment of Atopic Dermatitis. It functions as a potent JAK1/Tyk2 small molecule inhibitor. Preclinical assessment of TDM-180935 has demonstrated efficacy in multiple models and that it is well-suited for topical administration. Functional cell assays demonstrate that TDM-180935 can effectively suppress both keratinocyte- and T cell-derived pathogenic pathways characteristic for Atopic Dermatitis. Testing in rats and minipigs demonstrated favorable toxicology and toxicokinetic profiles. 

About Atopic Dermatitis (AD)

Atopic Dermatitis (AD), also called eczema, is a chronic relapsing pruritic inflammatory skin disorder that typically affects the face, neck, hands and feet, and flexor aspects of extremities. Depending on disease stages (acute, subacute, chronic), typical AD lesions include redness, swelling, cracked or excoriated skin, scaly erythema or plaques with or without exudates, and lichenification, accompanied by severe pruritus and skin dryness. Repeated scratching triggers a self-perpetuating itch-scratch cycle, which can have a significant impact on quality of life. The worldwide prevalence of AD is estimated to be 15-20% in children and 1-3% in adults, and the incidence has increased by 2- to 3-fold during the past decades in industrialized countries. The pathogenesis of AD involves four major aspects: disruption of skin barrier function, exposure to allergens, microbial infection, and dysregulated immune function. There are two major risk factors of developing AD: one is the genetic defect in the gene FLG encoding profilaggrin, the precursor of filaggrin protein present in the granular layer of the epidermis where it brings structural proteins together to create a strong barrier matrix; the other major risk factor is a family history of atopic diseases such as food allergy, allergic rhinitis, and asthma.

About Technoderma Medicines

Technoderma Medicines, Inc. is a privately held clinical stage biopharmaceutical company. The Company was originally located in Jiaxing Xiuzhou Biomedicine Guoqian Park, China, and recently relocated to Chengdu Tianfu BioPark, Sichuan, China. Its current core programs focus on development of innovative therapies for Androgenetic Alopecia, Atopic Dermatitis, Psoriasis and Lupus Erythematosus. Its "first-in-class" small molecule thyromimetic drug candidate TDM-105795 for Androgenetic Alopecia is currently completing Phase 2a clinical testing. Technoderma’s novel JAK1/TYK2 inhibitor TDM-180935 for Atopic Dermatitis has now completed Phase 1 clinical testing. The pipeline targets dermatologic indications.

INVESTOR AND MEDIA CONTAC

Technoderma Medicines, Inc.

Zengquan Wang, PhD, CEO

info@tkskin.com

色窝窝亚洲av网在线观看| 精品久久久久久综合日本| 性动态图av无码专区| 国产精品成人aaaaa网站| 亚洲另类无码专区首页| 国产精品国产三级在线...| 精品一区二区三区在线观看| 亚洲av色香蕉一区二区| 无遮挡边吃摸边吃奶边做| 50岁熟妇大白屁股真爽| 精品高朝久久久久9999| 夜鲁鲁鲁夜夜综合视频欧美| 日本老熟欧美老熟妇| 国产情侣久久久久aⅴ免费| 少妇高潮惨叫久久久久久电影 | 蜜臀av无码人妻精品| 亚洲综合天堂av网站在线观看| av不卡国产在线观看| 久久99久国产麻精品66| 欧美精品免费观看二区| 蜜臀久久99精品久久久久久小说| 97久久精品亚洲中文字幕无码| 日本va在线视频播放| 久久婷婷五月综合国产尤物app| 老太脱裤让老头玩ⅹxxxx| 精品久久亚洲中文无码| 国内揄拍国内精品人妻浪潮av| 国产成人涩涩涩视频在线观看| 亚洲精品成人无码中文毛片| 一边做一边喷17p亚洲乱妇50p| 国产不卡视频一区二区三区 | 国产露脸精品产三级国产av| 亚洲人成无码www久久久| 免费观看黄网站在线播放| 全免费a级毛片免费看网站| 99国产精品无码| 成年无码av片在线| 国产亚洲精品久久久ai换| 国产97在线 | 亚洲| 久久夜色精品国产噜噜亚洲av| 国产一卡2卡3卡四卡国色天香 |